Schneider MR - Search Results

1

Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.

Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K, Klocker H. Culig Z, et al. Among authors: schneider mr. Br J Cancer. 1999 Sep;81(2):242-51. doi: 10.1038/sj.bjc.6690684. Br J Cancer. 1999. PMID: 10496349 Free PMC article.

2

The future of antihormone therapy: innovations based on an established principle.

Parczyk K, Schneider MR. Parczyk K, et al. Among authors: schneider mr. J Cancer Res Clin Oncol. 1996;122(7):383-96. doi: 10.1007/BF01212877. J Cancer Res Clin Oncol. 1996. PMID: 8690748 Review.

3

Studies on the development of resistance to the pure antiestrogen Faslodex in three human breast cancer cell lines.

Sommer A, Hoffmann J, Lichtner RB, Schneider MR, Parczyk K. Sommer A, et al. Among authors: schneider mr. J Steroid Biochem Mol Biol. 2003 May;85(1):33-47. doi: 10.1016/s0960-0760(03)00139-0. J Steroid Biochem Mol Biol. 2003. PMID: 12798355

4

Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer.

Hoffmann J, Bohlmann R, Heinrich N, Hofmeister H, Kroll J, Künzer H, Lichtner RB, Nishino Y, Parczyk K, Sauer G, Gieschen H, Ulbrich HF, Schneider MR. Hoffmann J, et al. Among authors: schneider mr. J Natl Cancer Inst. 2004 Feb 4;96(3):210-8. doi: 10.1093/jnci/djh022. J Natl Cancer Inst. 2004. PMID: 14759988

5

Growth-stimulating effect of adrenal androgens on the R3327 Dunning prostatic carcinoma.

Schiller CD, Schneider MR, Hartmann H, Graf AH, Klocker H, Bartsch G. Schiller CD, et al. Among authors: schneider mr. Urol Res. 1991;19(1):7-13. doi: 10.1007/BF00294013. Urol Res. 1991. PMID: 1827559

6

Antiangiogenic chemotherapeutic agents: characterization in comparison to their tumor growth inhibition in human renal cell carcinoma models.

Schirner M, Hoffmann J, Menrad A, Schneider MR. Schirner M, et al. Among authors: schneider mr. Clin Cancer Res. 1998 May;4(5):1331-6. Clin Cancer Res. 1998. PMID: 9607594

7

Antiprogestin-progesterone interactions.

Michna H, Fritzemeier KH, Parczyk K, Nishino Y, Schneider MR. Michna H, et al. Among authors: schneider mr. Cancer Treat Res. 1996;83:191-212. doi: 10.1007/978-1-4613-1259-8_10. Cancer Treat Res. 1996. PMID: 8826648 Review. No abstract available.

8

Differential cross-talk of estrogen and growth factor receptors in two human mammary tumor cell lines.

Lichtner RB, Parczyk K, Birchmeier W, Schneider MR. Lichtner RB, et al. Among authors: schneider mr. J Steroid Biochem Mol Biol. 1999 Dec 31;71(5-6):181-9. doi: 10.1016/s0960-0760(99)00136-3. J Steroid Biochem Mol Biol. 1999. PMID: 10704907

9

A highly sensitive model for quantification of in vivo tumor angiogenesis induced by alginate-encapsulated tumor cells.

Hoffmann J, Schirner M, Menrad A, Schneider MR. Hoffmann J, et al. Among authors: schneider mr. Cancer Res. 1997 Sep 1;57(17):3847-51. Cancer Res. 1997. PMID: 9288798

10

Differentiation therapy with progesterone antagonists.

Michna H, Parczyk K, Schneider MR, Nishino Y. Michna H, et al. Among authors: schneider mr. Ann N Y Acad Sci. 1995 Jun 12;761:224-47. doi: 10.1111/j.1749-6632.1995.tb31381.x. Ann N Y Acad Sci. 1995. PMID: 7625723 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

256 results

Search Page

Filters